{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:12:04Z","timestamp":1791846724929,"version":"4.3.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-24192-4","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T13:55:10Z","timestamp":1763474110000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Progestin primed ovarian stimulation yields comparable outcomes to the GnRH antagonist protocol for controlled ovarian hyperstimulation"],"prefix":"10.1038","volume":"15","author":[{"given":"Elif","family":"Meseci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabri Berkem","family":"Okten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sevgi","family":"Bilgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakan","family":"Ozveri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nalise","family":"Ocal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bar\u0131shan","family":"Ozdemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cem","family":"F\u0131c\u0131c\u0131oglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"key":"24192_CR1","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.fertnstert.2022.06.012","volume":"118","author":"H Chen","year":"2022","unstructured":"Chen, H. et al. Comparison of the cumulative live birth rates after 1 in vitro fertilization cycle in women using gonadotropin-releasing hormone antagonist protocol vs. progestin-primed ovarian stimulation: A propensity score-matched study. Fertil. Steril. 118, 701\u2013712 (2022).","journal-title":"Fertil. Steril."},{"key":"24192_CR2","doi-asserted-by":"publisher","first-page":"1117513","DOI":"10.3389\/fendo.2023.1117513","volume":"14","author":"R Zhou","year":"2023","unstructured":"Zhou, R. et al. Comparison of cumulative live birth rates between progestin-primed ovarian stimulation protocol and gonadotropin-releasing hormone antagonist protocol in different populations. Front. Endocrinol. (Lausanne) 14, 1117513 (2023).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"24192_CR3","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/humupd\/8.2.129","volume":"8","author":"MJ Pelinck","year":"2002","unstructured":"Pelinck, M. J., Hoek, A., Simons, A. H. M. & Heineman, M. J. Efficacy of natural cycle IVF: A review of the literature. Hum. Reprod. Update 8, 129\u2013139 (2002).","journal-title":"Hum. Reprod. Update"},{"key":"24192_CR4","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1210\/clinem\/dgae847","volume":"110","author":"R Zhou","year":"2025","unstructured":"Zhou, R. et al. Comparison of cumulative live birth rates between progestin and GnRH analogues in preimplantation genetic testing cycles. J. Clin. Endocrinol. Metab. 110, 611\u2013623 (2025).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"24192_CR5","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1477-7827-10-26","volume":"10","author":"R Depalo","year":"2012","unstructured":"Depalo, R. et al. GnRH agonist versus GnRH antagonist in in vitro fertilization and embryo transfer (IVF\/ET). Reprod. Biol. Endocrinol. 10, 26 (2012).","journal-title":"Reprod. Biol. Endocrinol."},{"key":"24192_CR6","doi-asserted-by":"publisher","first-page":"170","DOI":"10.4103\/0974-1208.142476","volume":"7","author":"P Kumar","year":"2014","unstructured":"Kumar, P. & Sharma, A. Gonadotropin-releasing hormone analogs: Understanding advantages and limitations. J. Hum. Reprod. Sci. 7, 170\u2013174 (2014).","journal-title":"J. Hum. Reprod. Sci."},{"key":"24192_CR7","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.fertnstert.2015.03.022","volume":"104","author":"Y Kuang","year":"2015","unstructured":"Kuang, Y. et al. Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. Fertil. Steril. 104, 62-70.e3 (2015).","journal-title":"Fertil. Steril."},{"key":"24192_CR8","first-page":"CD001750","volume":"4","author":"HG Al-Inany","year":"2016","unstructured":"Al-Inany, H. G. et al. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst. Rev. 4, CD001750 (2016).","journal-title":"Cochrane Database Syst. Rev."},{"key":"24192_CR9","doi-asserted-by":"publisher","first-page":"e0175985","DOI":"10.1371\/journal.pone.0175985","volume":"12","author":"R Wang","year":"2017","unstructured":"Wang, R., Lin, S., Wang, Y., Qian, W. & Zhou, L. Comparisons of GnRH antagonist protocol versus GnRH agonist long protocol in patients with normal ovarian reserve: A systematic review and meta-analysis. PLoS ONE 12, e0175985 (2017).","journal-title":"PLoS ONE"},{"key":"24192_CR10","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1093\/humupd\/dmx017","volume":"23","author":"CB Lambalk","year":"2017","unstructured":"Lambalk, C. B. et al. GnRH antagonist versus long agonist protocols in IVF: A systematic review and meta-analysis accounting for patient type. Hum. Reprod. Update 23, 560\u2013579 (2017).","journal-title":"Hum. Reprod. Update"},{"key":"24192_CR11","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.fertnstert.2013.09.007","volume":"101","author":"Y Kuang","year":"2014","unstructured":"Kuang, Y. et al. Luteal-phase ovarian stimulation is feasible for producing competent oocytes in women undergoing in vitro fertilization\/intracytoplasmic sperm injection treatment, with optimal pregnancy outcomes in frozen-thawed embryo transfer cycles. Fertil. Steril. 101, 105\u2013111 (2014).","journal-title":"Fertil. Steril."},{"key":"24192_CR12","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s00404-018-4856-8","volume":"298","author":"N Iwami","year":"2018","unstructured":"Iwami, N. et al. New trial of progestin-primed ovarian stimulation using dydrogesterone versus a typical GnRH antagonist regimen in assisted reproductive technology. Arch. Gynecol. Obstet. 298, 663\u2013671 (2018).","journal-title":"Arch. Gynecol. Obstet."},{"key":"24192_CR13","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1093\/humrep\/dez034","volume":"34","author":"R Beguer\u00eda","year":"2019","unstructured":"Beguer\u00eda, R., Garc\u00eda, D., Vassena, R. & Rodr\u00edguez, A. Medroxyprogesterone acetate versus ganirelix in oocyte donation: A randomized controlled trial. Hum. Reprod. 34, 872\u2013880 (2019).","journal-title":"Hum. Reprod."},{"key":"24192_CR14","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.rbmo.2020.01.027","volume":"40","author":"P Alexandru","year":"2020","unstructured":"Alexandru, P., Cekic, S. G., Yildiz, S., Turkgeldi, E. & Ata, B. Progestins versus GnRH analogues for pituitary suppression during ovarian stimulation for assisted reproductive technology: A systematic review and meta-analysis. Reprod. Biomed. Online 40, 894\u2013903 (2020).","journal-title":"Reprod. Biomed. Online"},{"key":"24192_CR15","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1111\/1471-0528.14622","volume":"124","author":"J Dong","year":"2017","unstructured":"Dong, J. et al. The pregnancy outcome of progestin-primed ovarian stimulation using 4 versus 10 mg of medroxyprogesterone acetate per day in infertile women undergoing in vitro fertilisation: A randomised controlled trial. BJOG 124, 1048\u20131055 (2017).","journal-title":"BJOG"},{"key":"24192_CR16","doi-asserted-by":"publisher","first-page":"e2939","DOI":"10.1097\/MD.0000000000002939","volume":"95","author":"Y Wang","year":"2016","unstructured":"Wang, Y. et al. Controlled ovarian stimulation using medroxyprogesterone acetate and hMG in patients with polycystic ovary syndrome treated for IVF: A double-blind randomized crossover clinical trial. Medicine (Baltimore) 95, e2939 (2016).","journal-title":"Medicine (Baltimore)"},{"key":"24192_CR17","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1093\/humupd\/dmaa040","volume":"27","author":"B Ata","year":"2021","unstructured":"Ata, B., Capuzzo, M., Turkgeldi, E., Yildiz, S. & La Marca, A. Progestins for pituitary suppression during ovarian stimulation for ART: A comprehensive and systematic review including meta-analyses. Hum. Reprod. Update 27, 48\u201366 (2021).","journal-title":"Hum. Reprod. Update"},{"key":"24192_CR18","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1080\/09513590.2019.1604662","volume":"35","author":"F Mart\u00ednez","year":"2019","unstructured":"Mart\u00ednez, F. et al. Ovarian response in oocyte donation cycles under LH suppression with GnRH antagonist or desogestrel progestin: Retrospective and comparative study. Gynecol. Endocrinol. Off. J. Int. Soc. Gynecol. Endocrinol. 35, 884\u2013889 (2019).","journal-title":"Gynecol. Endocrinol. Off. J. Int. Soc. Gynecol. Endocrinol."},{"key":"24192_CR19","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s11596-019-2055-x","volume":"39","author":"Z-N Xiao","year":"2019","unstructured":"Xiao, Z.-N., Peng, J.-L., Yang, J. & Xu, W.-M. Flexible GnRH antagonist protocol versus progestin-primed ovarian stimulation (PPOS) protocol in patients with polycystic ovary syndrome: Comparison of clinical outcomes and ovarian response. Curr. Med. Sci. 39, 431\u2013436 (2019).","journal-title":"Curr. Med. Sci."},{"key":"24192_CR20","doi-asserted-by":"publisher","first-page":"796","DOI":"10.3389\/fendo.2019.00796","volume":"10","author":"Q Chen","year":"2019","unstructured":"Chen, Q. et al. Progestin vs. gonadotropin-releasing hormone antagonist for the prevention of premature luteinizing hormone surges in poor responders undergoing in vitro fertilization treatment: A randomized controlled trial. Front. Endocrinol. (Lausanne) 10, 796 (2019).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"24192_CR21","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1093\/humrep\/deae047","volume":"39","author":"MDM Vidal","year":"2024","unstructured":"Vidal, M. D. M., Mart\u00ednez, F., Rodr\u00edguez, I. & Polyzos, N. P. Ovarian response and embryo ploidy following oral micronized progesterone-primed ovarian stimulation versus GnRH antagonist protocol. A prospective study with repeated ovarian stimulation cycles. Hum. Reprod. 39, 1098\u20131104 (2024).","journal-title":"Hum. Reprod."},{"key":"24192_CR22","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1007\/s10815-015-0595-y","volume":"32","author":"J Cohen","year":"2015","unstructured":"Cohen, J., Chabbert-Buffet, N. & Darai, E. Diminished ovarian reserve, premature ovarian failure, poor ovarian responder\u2014A plea for universal definitions. J. Assist. Reprod. Genet. 32, 1709\u20131712 (2015).","journal-title":"J. Assist. Reprod. Genet."},{"key":"24192_CR23","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1093\/humrep\/deab117","volume":"36","author":"SJ Bhatt","year":"2021","unstructured":"Bhatt, S. J., Marchetto, N. M., Roy, J., Morelli, S. S. & McGovern, P. G. Pregnancy outcomes following in vitro fertilization frozen embryo transfer (IVF-FET) with or without preimplantation genetic testing for aneuploidy (PGT-A) in women with recurrent pregnancy loss (RPL): A SART-CORS study. Hum. Reprod. 36, 2339\u20132344 (2021).","journal-title":"Hum. Reprod."},{"key":"24192_CR24","doi-asserted-by":"publisher","first-page":"4461","DOI":"10.2147\/DDDT.S230129","volume":"13","author":"J Huang","year":"2019","unstructured":"Huang, J. et al. Progestin-primed ovarian stimulation with dydrogesterone versus medroxyprogesterone acetate in women with polycystic ovarian syndrome for in vitro fertilization: A retrospective cohort study. Drug Des. Devel. Ther. 13, 4461\u20134470 (2019).","journal-title":"Drug Des. Devel. Ther."},{"key":"24192_CR25","first-page":"378","volume":"1999","author":"DK Gardner","year":"1999","unstructured":"Gardner, D. K. In-vitro culture of human blastocysts. Towar. Reprod. Certain. Fertil. Genet. beyond 1999, 378\u2013388 (1999).","journal-title":"Towar. Reprod. Certain. Fertil. Genet. beyond"},{"issue":"3","key":"24192_CR26","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s11596-019-2055-x","volume":"39","author":"ZN Xiao","year":"2019","unstructured":"Xiao, Z. N., Peng, J. L., Yang, J. & Xu, W. M. Flexible GnRH antagonist protocol versus progestin-primed ovarian stimulation (PPOS) protocol in patients with polycystic ovary syndrome: Comparison of clinical outcomes and ovarian response. Curr. Med. Sci. 39(3), 431\u2013436 (2019).","journal-title":"Curr. Med. Sci."},{"key":"24192_CR27","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3758\/BF03193146","volume":"39","author":"F Faul","year":"2007","unstructured":"Faul, F., Erdfelder, E., Lang, A.-G. & Buchner, A. G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav. Res. Methods 39, 175\u2013191 (2007).","journal-title":"Behav. Res. Methods"},{"key":"24192_CR28","doi-asserted-by":"publisher","first-page":"e0145895","DOI":"10.1371\/journal.pone.0145895","volume":"11","author":"B Huang","year":"2016","unstructured":"Huang, B. et al. Elevated progesterone levels on the day of Oocyte maturation may affect top quality embryo IVF cycles. PLoS ONE 11, e0145895 (2016).","journal-title":"PLoS ONE"},{"key":"24192_CR29","doi-asserted-by":"publisher","first-page":"e0176482","DOI":"10.1371\/journal.pone.0176482","volume":"12","author":"VS Vanni","year":"2017","unstructured":"Vanni, V. S. et al. Top quality blastocyst formation rates in relation to progesterone levels on the day of oocyte maturation in GnRH antagonist IVF\/ICSI cycles. PLoS ONE 12, e0176482 (2017).","journal-title":"PLoS ONE"},{"key":"24192_CR30","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13048-020-00620-z","volume":"13","author":"E Mathieu d\u2019Argent","year":"2020","unstructured":"Mathieu d\u2019Argent, E. et al. Outcomes of fertility preservation in women with endometriosis: comparison of progestin-primed ovarian stimulation versus antagonist protocols. J. Ovarian Res. 13, 18 (2020).","journal-title":"J. Ovarian Res."},{"key":"24192_CR31","first-page":"671","volume":"17","author":"M Eftekhar","year":"2019","unstructured":"Eftekhar, M., Hoseini, M. & Saeed, L. Progesterone-primed ovarian stimulation in polycystic ovarian syndrome: An RCT. Int. J. Reprod. Biomed. 17, 671\u2013676 (2019).","journal-title":"Int. J. Reprod. Biomed."},{"key":"24192_CR32","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jogoh.2018.10.008","volume":"48","author":"P Huang","year":"2019","unstructured":"Huang, P., Tang, M. & Qin, A. Progestin-primed ovarian stimulation is a feasible method for poor ovarian responders undergoing in IVF\/ICSI compared to a GnRH antagonist protocol: A retrospective study. J. Gynecol. Obstet. Hum. Reprod. 48, 99\u2013102 (2019).","journal-title":"J. Gynecol. Obstet. Hum. Reprod."},{"key":"24192_CR33","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1080\/14647273.2020.1794060","volume":"25","author":"E Turkgeldi","year":"2022","unstructured":"Turkgeldi, E. et al. Effectiveness of the flexible progestin primed ovarian stimulation protocol compared to the flexible GnRH antagonist protocol in women with decreased ovarian reserve. Hum. Fertil. (Camb) 25, 306\u2013312 (2022).","journal-title":"Hum. Fertil. (Camb)"},{"key":"24192_CR34","doi-asserted-by":"publisher","first-page":"702558","DOI":"10.3389\/fendo.2021.702558","volume":"12","author":"S Guan","year":"2021","unstructured":"Guan, S., Feng, Y., Huang, Y. & Huang, J. Progestin-primed ovarian stimulation protocol for patients in assisted reproductive technology: A meta-analysis of randomized controlled trials. Front. Endocrinol. 12, 702558 (2021).","journal-title":"Front. Endocrinol."},{"key":"24192_CR35","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1007\/s00404-023-07269-1","volume":"309","author":"R Deng","year":"2024","unstructured":"Deng, R. et al. GnRH antagonist protocol versus progestin-primed ovarian stimulation in patients with polycystic ovary syndrome: A systematic review and meta-analysis. Arch. Gynecol. Obstet. 309, 1151\u20131163 (2024).","journal-title":"Arch. Gynecol. Obstet."},{"key":"24192_CR36","doi-asserted-by":"publisher","first-page":"110","DOI":"10.2174\/0929867327666200316142659","volume":"28","author":"A Samadi","year":"2021","unstructured":"Samadi, A. et al. A comprehensive review on oxysterols and related diseases. Curr. Med. Chem. 28, 110\u2013136 (2021).","journal-title":"Curr. Med. Chem."},{"key":"24192_CR37","doi-asserted-by":"publisher","first-page":"2414783","DOI":"10.1080\/09513590.2024.2414783","volume":"40","author":"VN Lokshin","year":"2024","unstructured":"Lokshin, V. N. et al. Progestin-primed ovarian stimulation outcomes in in-vitro fertilization (IVF)\u2014A systematic review of the literature. Gynecol. Endocrinol. 40, 2414783 (2024).","journal-title":"Gynecol. Endocrinol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24192-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24192-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24192-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T02:02:56Z","timestamp":1763517776000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24192-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["24192"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-24192-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,18]]},"assertion":[{"value":"23 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"40568"}}